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One might be excused for being tempted to answer the
title’s question in the negative without second thoughts.
Nevertheless, we felt that this was the right moment to
explore it further, by illustration with three bacteria—Klebsi-
ella pneumoniae, Mycobacterium tuberculosis, and Staphylococcus
aureus—for two reasons:
1 there has been growing, although perhaps hesitant, pub-
lished evidence that, depending on the organism, the
drug, and the localization of the infection, the answer to
this deceptively obvious-sounding question may not
always be an unequivocal ‘no’;
2 there are increasingly urgent discussions among clinical
doctors whose daily practice and unpublished data would
point in the same direction.
This second reason seemed to beg for an attempt at summa-
rizing, in as systematic a fashion as feasible, the evidence
mentioned as the ﬁrst reason—hence the present theme
section.
So, the answer to our question would seem, in turn, to
hinge on three subsidiary questions:
1 Should the clinical doctor really care about the presence
of genes whose expression could cause resistance to a
drug, when this drug can be delivered to the site of
infection in such a way that this resistance does not com-
promise therapeutic success?
2 Are the conditions for (1) above easily achieved by doc-
tors and safe for patients?
3 If they are so far only safe and effective for patients, how
can their application and adoption by doctors be
improved?
In his review, Bottger focuses on the current methodological
shortcomings when deﬁning M. tuberculosis isolates as suscep-
tible or resistant to speciﬁc drugs [1]. Contrary to what is
habitual practice for other bacteria, a continuous spectrum
of drug dilutions is not used for M. tuberculosis, occasionally
leaving a signiﬁcant gap between the in vitro deﬁnition—using
only ‘breakpoint’ drug concentrations—of an isolate as resis-
tant, and obtaining in vivo drug levels sufﬁcient to eliminate it.
Therefore, Bottger urgently proposes a continuous-spectrum
methodology—the challenge here being its timely multi-
centre validation and its disseminated adoption, to replace
the current, decades old system.
For S. aureus, on the other hand, Uekotter et al. conclude
that, as far as methicillin-resistant S. aureus and glycopeptide
intermediate-resistant S. aureus are concerned, no such gap
exists, and the question has, indeed, to be answered in the
negative [2]. Despite two reports in which empirical—and
therefore, in many instances, inappropriate—treatment of
S. aureus bacteraemia did not compare unfavourably with
appropriate treatment, these authors’ overall assessment of
the literature casts doubts even on the in vivo beneﬁts of
synergy by non-cell wall-active compounds with b-lactams
and glycopeptides.
Daikos and Markogiannakis were perhaps more fortunate
in having available for review a number of animal model,
pharmacokinetic and pharmacodynamic studies performed to
examine whether, and when, an infection by a carbapenem-
ase-producing K. pneumoniae isolate may still be successfully
treated with a carbapenem [3]. These different approaches
seem to converge on the suggestion that, provided a ﬁt-
for-purpose drug regimen is observed, when the carbapenem
MIC is equal or lower to 4 mg/L, the infection may still be
treatable, even if caused by a carbapenemase-producing
K. pneumoniae isolate.
And so we come full circle to the crucial importance of
characteristics determined by the laboratory, such as MICs,
in determining the clinical approach to an infection. It
would therefore seem fair to suggest that qualifying the lab-
oratory-inﬂuenced concept that ‘presence of an in vitro
identiﬁed resistance mechanism equals therapeutic failure’,
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while simultaneously intensifying and ﬁne-tuning studies on
drug efﬁcacy in vivo (whether in animal model experiments
or through the continued, systematic gathering of clinical
data), might still be an approach that is likely to yield signif-
icant and welcome clinical beneﬁts for some bacterial infec-
tions. At any rate, we sincerely hope that the present
theme section will keep the relevant discussions lively.
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